12/4/2024

Janusmed kön och genus

Janusmed kön och genus – PREZISTA

Janusmed kön och genus är ett kunskapsstöd som tillhandahåller information om köns- och genusaspekter på läkemedelsbehandling. Kunskapsstödet är avsedd främst för hälso- och sjukvårdspersonal. Texterna är generella och ska inte ses som behandlingsriktlinjer. Det är alltid behandlande läkare som ansvarar för patientens medicinering.

För att komma till startsidan för Janusmed kön och genus och för att göra sökningar klicka här.

Tillbaka till index
A A
A A

Darunavir

Darunavir

Klass : A

Visa all info

Skriv ut

Kontakta oss

  1. PREZISTA (darunavir). Summary of Product Characteristics. European Medicines Agency (EMA); 2009.

  2. Schöller-Gyüre M, Kakuda TN, Sekar V, Woodfall B, De Smedt G, Lefebvre E et al. Pharmacokinetics of darunavir/ritonavir and TMC125 alone and coadministered in HIV-negative volunteers. Antivir Ther. 2007;12:789-96.

  3. Ghosn J, Slama L, Chermak A, Houssaini A, Lambert-Niclot S, Schneider L et al. Switching to darunavir/ritonavir 800/100 mg once-daily containing regimen maintains virological control in fully suppressed pre-treated patients infected with HIV-1. J Med Virol. 2013;85:8-15.

  4. Patterson K, Jennings S, Falcon R, Mrus J, Kashuba A. Darunavir, ritonavir, and etravirine pharmacokinetics in the cervicovaginal fluid and blood plasma of HIV-infected women. Antimicrob Agents Chemother. 2011;55:1120-2.

  5. Haubrich R, Berger D, Chiliade P, Colson A, Conant M, Gallant J et al. Week 24 efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients. AIDS. 2007;21:F11-8.

  6. Katlama C, Esposito R, Gatell JM, Goffard JC, Grinsztejn B, Pozniak A et al. Efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients: 24-week results of POWER 1. AIDS. 2007;21:395-402.

  7. Currier J, Averitt Bridge D, Hagins D, Zorrilla CD, Feinberg J, Ryan R et al. Sex-based outcomes of darunavir-ritonavir therapy: a single-group trial. Ann Intern Med. 2010;153:349-57.

  8. Fourie J, Flamm J, Rodriguez-French A, Kilby D, Domingo P, Lazzarin A et al. Effect of baseline characteristics on the efficacy and safety of once-daily darunavir/ ritonavir in HIV-1-infected, treatment-naïve ARTEMIS patients at week 96. HIV Clin Trials. 2011;12:313-22.

  9. Currier JS, Martorell C, Osiyemi O, Yin MT, Ryan R, De La Rosa G et al. Effects of darunavir/ritonavir-based therapy on metabolic and anthropometric parameters in women and men over 48 weeks. AIDS Patient Care STDS. 2011;25:333-40.

  10. Else LJ, Taylor S, Back DJ, Khoo SH. Pharmacokinetics of antiretroviral drugs in anatomical sanctuary sites: the male and female genital tract. Antivir Ther. 2011;16(8):1149-67.

  11. Läkemedelsstatistik. Stockholm: Socialstyrelsen. 2016 [cited 2017-05-20.]

  1. PREZISTA (darunavir). Summary of Product Characteristics. European Medicines Agency (EMA); 2009.
  2. Schöller-Gyüre M, Kakuda TN, Sekar V, Woodfall B, De Smedt G, Lefebvre E et al. Pharmacokinetics of darunavir/ritonavir and TMC125 alone and coadministered in HIV-negative volunteers. Antivir Ther. 2007;12:789-96.
  3. Ghosn J, Slama L, Chermak A, Houssaini A, Lambert-Niclot S, Schneider L et al. Switching to darunavir/ritonavir 800/100 mg once-daily containing regimen maintains virological control in fully suppressed pre-treated patients infected with HIV-1. J Med Virol. 2013;85:8-15.
  4. Patterson K, Jennings S, Falcon R, Mrus J, Kashuba A. Darunavir, ritonavir, and etravirine pharmacokinetics in the cervicovaginal fluid and blood plasma of HIV-infected women. Antimicrob Agents Chemother. 2011;55:1120-2.
  5. Haubrich R, Berger D, Chiliade P, Colson A, Conant M, Gallant J et al. Week 24 efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients. AIDS. 2007;21:F11-8.
  6. Katlama C, Esposito R, Gatell JM, Goffard JC, Grinsztejn B, Pozniak A et al. Efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients: 24-week results of POWER 1. AIDS. 2007;21:395-402.
  7. Currier J, Averitt Bridge D, Hagins D, Zorrilla CD, Feinberg J, Ryan R et al. Sex-based outcomes of darunavir-ritonavir therapy: a single-group trial. Ann Intern Med. 2010;153:349-57.
  8. Fourie J, Flamm J, Rodriguez-French A, Kilby D, Domingo P, Lazzarin A et al. Effect of baseline characteristics on the efficacy and safety of once-daily darunavir/ ritonavir in HIV-1-infected, treatment-naïve ARTEMIS patients at week 96. HIV Clin Trials. 2011;12:313-22.
  9. Currier JS, Martorell C, Osiyemi O, Yin MT, Ryan R, De La Rosa G et al. Effects of darunavir/ritonavir-based therapy on metabolic and anthropometric parameters in women and men over 48 weeks. AIDS Patient Care STDS. 2011;25:333-40.
  10. Else LJ, Taylor S, Back DJ, Khoo SH. Pharmacokinetics of antiretroviral drugs in anatomical sanctuary sites: the male and female genital tract. Antivir Ther. 2011;16(8):1149-67.
  11. Läkemedelsstatistik. Stockholm: Socialstyrelsen. 2016 [cited 2017-05-20.]